

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS**

JOHN HANCOCK LIFE INSURANCE
COMPANY, JOHN HANCOCK VARIABLE
LIFE INSURANCE COMPANY, and
MANULIFE INSURANCE COMPANY (f/k/a
INVESTORS PARTNER INSURANCE
COMPANY),

Plaintiffs,

v.

ABBOTT LABORATORIES,

Defendants.

CIVIL ACTION NO. 05-11150-DPW
Hon. Judge Douglas P. Woodlock

**ABBOTT LABORATORIES' TRIAL EXHIBIT LIST WITH REVISED OBJECTIONS
FROM JOHN HANCOCK LIFE INSURANCE COMPANY, ET AL.**

Defendant Abbott Laboratories (“Abbott”) respectfully submits its Objected To Trial Exhibit List with additional objections that it has received from Hancock. Attached as Exhibit A is Hancock’s key to its objections. Attached as Exhibit B is Abbott’s Trial Exhibit List with Hancock’s additional objections. Abbott notes that Hancock has not objected to many of these documents. Abbott has not changed the letter designations of these exhibits because many of Abbott’s previous filings, including its affidavits and deposition designations, refer to these exhibits by these designations.

Respectfully submitted,

Dated: February 29, 2008

ABBOTT LABORATORIES

By its attorneys

/s/ Eric J. Lorenzini

Eric J. Lorenzini

Michael S. D'Orsi
Peter E. Gelhaar (BBO #188310)
Michael S. D'Orsi (BBO #566960)
DONNELLY, CONROY & GELHAAR LLP
1 Beacon St., 33rd Floor
Boston, Massachusetts 02108
(617) 720-2880

and

Jeffrey I. Weinberger (Admitted Pro Hac Vice)
Gregory D. Phillips (Admitted Pro Hac Vice)
Eric J. Lorenzini (Admitted Pro Hac Vice)
Ozge Guzelsu (Admitted Pro Hac Vice)
MUNGER, TOLLES & OLSON LLP
355 South Grand Avenue, 35th Floor
Los Angeles, CA 90071
(213) 683-9100

Counsel for Abbott Laboratories

CERTIFICATE OF SERVICE

I hereby certify that this document(s) filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non registered participants on February 29, 2008.

Date: February 29, 2008.

/s/ Eric J. Lorenzini

EXHIBIT A

John Hancock v. Abbott Laboratories**John Hancock's Objections to Abbott's Revised List of Proposed Trial Exhibits****Key**

Code	Objection
AUTH	The proposed exhibit does not sufficiently indicate that it is what it purports to be, and is inadmissible under Fed. R. Evid. 901.
BATES	The proposed exhibit denotes a Bates range that appears to be in error. John Hancock requests that Abbott properly identify the proposed exhibit. Further, John Hancock reserves all objections to these documents.
HEAR	The proposed exhibit is Hearsay or Double Hearsay not within any exception, and is inadmissible under Fed. R. Evid. 802
IRREL	The proposed exhibit is irrelevant under Fed. R. Evid. 401, and thus inadmissible under Fed. R. Evid. 402.
MULTI	The proposed exhibit identifies more than one document. John Hancock requests that Abbott identify these documents with separate exhibit numbers. John Hancock reserves all objections to such documents.
No Objection	John Hancock does not object to the proposed exhibit.
SETTL	The proposed exhibit deals with settlement discussions and is thus inadmissible under Fed. R. Evid. 408.
PLs' "xx"	Abbott's proposed trial exhibit has been proposed as a trial exhibit by John Hancock, and has been objected to by Abbott. John Hancock urges Abbott to withdraw its objection to documents that Abbott now offers as trial exhibits in its own case.
Ex. "xx"	Abbott's proposed trial exhibit has been proposed as a trial exhibit by John Hancock, and has not been objected to by Abbott. The exhibit exists on the parties' list of "Agreed To" exhibits.
UNTIMELY	The proposed exhibit is being submitted by Abbott as part of the expert report of Avram Tucker. The exhibit was not previously included in that expert report, as required under the Scheduling Order in this case, and under Fed. R. Civ. P. 26(a)(2)(B). Hancock therefore objects to the exhibit as untimely.

EXHIBIT B

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
11/01/2000	ABBT0006627 - ABBT0006700	Andrews_0004	Cohen Memo Attaching Diligence and Research Plan Presentation titled "NNRs and Pain: NNRs are Expressed in Pain Pathways" (Andrews 4)	Authenticity / Hearsay (ABBT0006627-8)
01/01/0000	AND00001 - AND0015		Bukozer Email re: ABBT773 Communication	Authenticity
7/11/2002	ABBT203446 - ABBT203450		DiMasi Article titled "Success Rates for New Drugs Entering Clinical Testing in the US" Purchase Recommendation re: Idun Pharmaceuticals Inc. (Blewitt 5)	Multiple Documents / Hearsay (ABBT203449 50)
00/00/2001	JH001446 - JH001459		Lai Email re: ABT-259 Summary Statement Draft # 2 (McCarthy 4)	Hearsay
3/24/1999	JHII012355 - JHII012367; JH00203080; Blewitt_0005	McCarthy_0004	Nader Article titled "New Antimicrobials: Facing Our Problems"	Multiple Documents
6/29/1999	JH002081 - JH002090		DePonti, Poluzzi & Montanero Article titled "QT Interval Prolongation by Non Cardiac Drugs Lessons to be Learned from Recent Experience"	Hearsay / Irrelevant
11/21/1999	ABBT0020546 - ABBT0020551		Collicott Email re: Resume Ketek Profile	Hearsay / Irrelevance / Authenticity
00/00/2000	JH000767 - JH000770	Klotz_0030	Study Report No. R&D/99/280 for ABT-594 Protocol M98833 June 20, 2000	Hearsay / Irrelevant
5/9/2000	ABBT242357 - ABBT242361	Collicut_0001	Klotz_0028	Research Analysis Report by Wigard Shaik Titled, "The Changing Face of Antihistamines and Cardiac Adverse Drug Reactions: A Clinical Perspective
5/11/2000	JH000747 - JH000761		Klotz_0029	MedWatch Summary of Safety Related Drug Labeling Changes Approved by FDA June 2000
6/20/2000	ABBT0510354 - ABBT0510483		Collicott Email re: ABT-594 Phase IIb Meeting	Hearsay / Irrelevant
07/00/2000				
8/11/2000				
9/15/2000	ABBT242156 - ABBT242156		Redacted version of Purchase Recommendation re: Abbott Labs ("Non-Recourse") with handwritten notes	Authenticity
10/10/2000	JH002373 - JH002390			
10/26/2000	JH007701 - JH007701		Pais Email re: Hancock [Information Regarding the Two Websites]	Hearsay
11/1/2000	JH003740 - JH003814		Tormey Email re: Funding Agreement	Irrelevant
11/10/2000	JH005273 - JH005348	Tormey_0011	Tormey Email re: Research Funding Agreement (Tormey 11)	Irrelevant
11/28/2000	ABBT314979 - ABBT314987	McCarthy_0031	Kuemmerle Email re: Neuroscience Portfolio Working Session for 1/12/0000: Technical Assessment (Silber 32 McCarthy 31)	Hearsay
01/00/2001	ABBT0010550 - ABBT0010576		2001 Portfolio Worksheets	Hearsay (ABBT0010574)

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
2/2/2001	ABBT292664 - ABBT294198		Dart Email re: Probabilities [Update Regarding the R&D Sheets]	Hearsay
2/15/2001	JH006299 - JH006359		Pals Email re: Research Funding Agreement	Hearsay / Irrelevant
2/28/2001	ABBT0576918 - ABBT0576923		Report re: CLARITHROMYCIN Japan Update	Hearsay
3/9/2001	JH008376 - JH008384		02/00/2001 Current Drug Development	
			Lee Facsimile re: Research Funding Agreement Draft	Irrelevant / Hearsay
3/13/2001	JH008074 - JH008211		Research Funding Agreement between Abbott Laboratories and John Hancock Life Insurance	Multiple Documents; JH008074-75; Irrelevant; JH008076-21; No Objection
3/16/2001	ABBT0012388 - ABBT0012390	Deemer_0017	Baker Email re: Revisions to the Oncology Portfolio Analysis Information (Deemer 17)	Hearsay / Authenticity
3/26/2001	ABBT360531 - ABBT360573		Woidat Email re: 773 Presentation	Hearsay
4/3/2001	ABBT0033510 - ABBT0033516		Kowaluk Email re: Oncology Probabilities Revised	Hearsay
4/27/2001	ABBT110591.JR - ABBT110591.UR		Fox Email re: FYI Ketek	Hearsay
5/4/2001	ABBT0054230 - ABBT0054231		Hansen Email re: Marimastat	Hearsay
5/9/2001	ABBT294559 - ABBT294560		Kowaluk Email re: ABT-594 Pain DSG	Hearsay
5/21/2001	ABBT0164581 - ABBT0164581		McCarthy Email re: ABT-594 Advisory Meeting?	Hearsay
6/7/2001	ABBT0054387 - ABBT0054387		D'Amico Email re: Update	Hearsay
7/9/2001	ABBT288530 - ABBT288530		Kowaluk Email re: 594 GPEC Prep	Hearsay
7/13/2001	ABBT209793 - ABBT209829		Kuemmerle Email re: ABT-773 Analysis; Reminder	Hearsay (ABBT209793-4)
8/6/2001	ABBT0049990 - ABBT0049990		Davidson Email to Nisen re: ABT-5-8 [Marimastat Shows Promise as Treatment for Unresectable Pancreatic Cancer]	Hearsay
8/16/2001	ABBT289332 - ABBT289344	McCarthy_0053	Kowaluk Email re: ABT-594 DSG Slides for PEMC Review (McCarthy 53)	Hearsay (ABBT289332)
9/20/2001	ABBT203477 - ABBT203484		C. Meyer Email thread re: Portfolio issues update	Hearsay
10/2/2001	ABBT201003 - ABBT201007	McCarthy_0057	Leonard Memo re: 10/08 PEC Meeting Agenda	Hearsay (ABBT201003)
10/9/2001	ABBT246335 - ABBT246335	Kowaluk_0030	Biannesen Email re: ABT-594 Project Team Update	Hearsay
7/11/2002	ABBT203446 - ABBT203453		Bukolizer Email re: ABT-773 Communication	Hearsay
8/6/2002	ABBT333998 - ABBT333998		Lyon's Email re: ABT-773	Hearsay
9/26/2002	AUDIT 002790 - AUDIT 002790		Elitra Pharmaceuticals ABT-773 Non-Binding Letter of Intent 09/26/02	Hearsay / Authenticity
10/16/2002	AUDIT 002791 - AUDIT 002793		Letter of Intent between Elitra Pharmaceuticals and Abbott Laboratories	Hearsay
12/6/2002	ABBT0518032 - ABBT0518034		Tyree Memo re: November 2002 Highlights	Hearsay
12/20/2002	JH009977 - JH009978		Johansson Letter re: Research Funding Agreement Dated as of 03/31/01	Hearsay
12/20/2002	JH000807 - JH000817	Hendrick_0008	Lyons Letter re: Research Funding Agreement Dated as of 03/13/01 (a) 2002 Program Status Report and Related Cost Summary (b) 2003 Preliminary Annual Research Plan (Hendricks 8)	Hearsay
2/28/2003	ABBT335048 - ABBT335050		Mathers Letter re: February Highlights	Used in Settlement Discussions and inadmissible under Fed. R. Evid. 408
11/12/2003	ABBT0004519 - ABBT0004520		Tyree Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
00/00/2004	CRA00127 - CRA00139		Hancock Program Funding Scenarios (Work Paper)	Hearsay

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
5/10/2004	ABBT0000057 - ABBT0000058		Desideri Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
5/18/2004	ABBT0000061 - ABBT0000064		Faximile of Desideri Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
6/10/2004	ABBT0190551 - ABBT0190552		Pavelske Email re: RICs boxes, Hancock audit	Hearsay
6/15/2004	ABBT0000077 - ABBT0000078		Desideri Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
8/5/2004	ABBT0000125 - ABBT0000127		Desideri Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
9/9/2004		Blewitt_0021	Affidavit of Stephen J. Blewitt (Blewitt 21)	Hearsay
10/27/2004	JHII011289 - JHII011291		Johnsson Letter re: Research Funding Agreement Dated as of 03/31/01	Hearsay
12/2/2004	JHII011295 - JHII011295		Tyree Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
12/3/2004	ABBT0126668 - ABBT0126669		Wittenberg Email re: John Hancock/Abbott Blewitt Memo re: Report Request # 85 (FOLLOW-UP)	Hearsay
9/6/2005	JHII012056 - JHII012061	Blewitt_0030	Valuation of Sch BA Part 1 Assets Abbott Laboratories (Blewitt 30)	Hearsay
12/6/2005	JHII012050 - JHII012055		Investment Review Report re: Execution Version of Agreement	Hearsay
5/25/2007		Fairweather_0003	Reece Letter re: John Hancock Life Insurance Co et al v Abbott Laboratories Civil Action Number 0511150DPW (Fairweather 3)	Hearsay
5/29/2007		Fairweather_0002	Flower Valley Consulting Inc. Web Article titled "Good Statistics Don't Happen by Chance" (Fairweather 2)	Hearsay
5/29/2007		Gold_0002	Edelstein Letter Forwarding List of Documents Relied Upon by Gold (Gold 2)	Hearsay / Irrelevant
5/29/2007		Gold_0003	Edelstein Letter Forwarding 2 Documents Relied Upon by Gold (Gold 3)	Hearsay
10/13/2006		Rodda_0003	Expert Report of Dr. Bruce Rodda	Hearsay
10/13/2006		Friedman_0001	Expert Report of Alan Friedman	Hearsay
1/19/2007		Tucker_0002	Expert Report of Avram S. Tucker	Hearsay
2/20/2007			Life Science Weekly Article titled, "Recent Reports from Advanced Life Sciences Holdings provided and update"	Hearsay
2/26/2007		Rodda_0002	Expert Report of Dr. Bruce Rodda (Statistical Issues)	Hearsay
6/11/2007			Crain's Chicago Business Article titled, "Waiting to Exhale. Day of Reckoning nears as biotech firm Advanced Life awaits trial results on new treatment for pneumonia" by Mike Colias	Hearsay
6/21/2007			Advanced Life Sciences News Release titled, "Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial"	Hearsay
6/29/2007			Crain's Chicago Business Article titled, "Waiting to Exhale. Clinical Trials" by Mike Colias	Hearsay
8/15/2007			Sanofi Aventis February 2007 internet Ketek product description	Hearsay

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
8/15/2007			U.S. Food and Drug Administration Center for Drug Evaluation and Research Web Page Article titled, "Drug-Induced Liver Toxicity"	Hearsay
08/21/2007			Life Science Weekly Article titled, "Reports from Advanced Life Sciences Holdings describe recent developments"	Hearsay
12/3/2007			Supplemental Expert Report of Avram S. Tucker Complain in <i>Hancock Life Ins. Co., et al. v Abbott Laboratories</i> , No. 03-12501 (<i>Hancock J.</i>) Desideri Letter re: Research Funding Agreement Dated 03/13/01	Hearsay Irrelevant
12/12/2003	ABBT00000071 - ABBT0000073		DAmore Letter re: <i>Hancock v. Abbott</i> DAmore Letter re: <i>Hancock v. Abbott</i>	Hearsay Hearsay
6/3/2004			Desideri Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
6/16/2004			September 29, 2004 Affidavit of Stephen J. Blewitt D'Amore Letter re: Research Funding Agreement Dated 08/14/01	Hearsay
6/18/2004			DAmore Letter re: Research Funding Agreement Dated 08/14/01	Hearsay
6/30/2004			Complaint Answer to Complaint	Hearsay Irrelevant
8/24/2004			Transcript of Court's Status Conference Hearing Abbott's Response to Hancock's First Request for Production of Documents	Hearsay Hearsay
9/29/2004			DAmore Letter re: <i>Hancock v. Abbott</i> , Case No. 05-11150-DPW	Hearsay
2/11/2005			DAmore Letter re: <i>Hancock v. Abbott</i> , Case No. 05-11150-DPW	Hearsay
2/15/2005			DAmore Letter re: Research Funding Agreement Dated 08/14/01	Hearsay
6/3/2005			DAmore Letter re: Research Funding Agreement Dated 08/14/01	Hearsay
6/3/2005			Complaint Answer to Complaint	Hearsay Irrelevant
7/29/2005			Transcript of Court's Status Conference Hearing Abbott's Response to Hancock's First Request for Production of Documents	Hearsay Hearsay
10/13/2005			DAmore Letter re: <i>Hancock v. Abbott</i> , Case No. 05-11150-DPW	Hearsay
11/7/2005			DAmore Letter re: <i>Hancock v. Abbott</i> , Case No. 05-11150-DPW	Hearsay
11/28/2005			DAmore Letter re: <i>Hancock v. Abbott</i> , Case No. 05-11150-DPW	Hearsay
12/9/2005			DAmore Letter re: <i>Hancock v. Abbott</i> , Case No. 05-11150-DPW	Hearsay
3/28/2006			Applied Discovery, Inc. Letter reflecting production of Bates Range ABBT200001-ABBT367508	Hearsay / Authenticity
6/23/2006	Friedman 0002	Klaus_0004A	Supplemental Complaint Abbott's Supplemental Responses and Objections To Plaintiffs' Rule 30(b)(6) Deposition Notice (Audit)	Hearsay Irrelevant
7/13/2006			Transcript of Hearing before Honorable Douglas P. Woodlock First Amended Supplemental Complaint Answer to Amended Complaint (Docket # 107)	Hearsay Irrelevant
12/6/2006			Guzelsu Letter enclosing documents Lorenzini Email re: interrogatory responses Transcript of Pre-trial Conference Davis letter attaching chart	Hearsay Irrelevant
12/29/2006			Lorenzini Email attaching Redline comparing First Amended Complaint to Second Amended Complaint Answer to Amended Complaint (Docket # 204)	Hearsay Irrelevant
1/12/2007			Rieser Email re: Azmi's Weekly Update Calendar Entry Meeting ABT- 594 Power Calculations with Siber, Morris, Leonard	Hearsay Hearsay
3/6/2007			Woidat Email re: ABT-594 2001 Budget	Hearsay
6/4/2007				
10/25/2007				
11/18/2007				
11/15/2007				
1/12/2007				
3/6/2007				
6/4/2007				
12/11/2000	ABBT0176908 - 0173909			
4/6/2001	ABBT0125549			
12/11/2000	ABBT354519 - ABBT354520			
5/23/2001				

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
8/16/2001	ABB1004863		Interoffice memorandum re: ABT-594 Review, August 21, 2001. Pharmaceutical Executive Management Committee	Hearsay
8/7/2001	ABB10126919 - ABBT0120921		Wise Email re: PECM 8/21 Agenda	Hearsay
10/5/2001	ABB1224537 - ABBT224539		Leonard Email re: New Agenda for Monday's PEC Meeting	Hearsay
10/5/2001	ABB1011238 - ABBT0111240		Chiozzi Email re: October 8 program	Hearsay
10/8/2001	ABB134009 - ABBT334011		Interoffice memorandum re: Monthly Highlights - September 2001	Hearsay
10/18/2001	ABB10165160 - ABBT0165162		Kowalki Email re: Highlights	Hearsay
11/15/2001	ABB1009617 - ABBT009618		McCarthy Email re: 2002 Goals	Hearsay
2/14/2003			Out-license Anti-infective Compounds Board Document February 14, 2003 Draft 8	Authenticity / Hearsay
3/27/2001	ABB1327314 - ABBT327327		Kowalki Email re: therapeutic strategy evaluations attaching briefing document portfolio review	Hearsay (ABB1327316-27)
12/12/2000	ABB10569030		Calendar Entry Rescheduled Meeting ABT-773 Project Review	Hearsay
4/27/2001	ABB143066.ur - ABBT143067.ur		Interoffice Memorandum re: Monthly Highlights April 2001	Hearsay
8/10/2001	ABB1003466 - ABBT003467		Interoffice Memorandum re: Monthly Highlights July 2001	Hearsay
10/8/2001	ABB1003482 - ABBT003484		Interoffice Memorandum re: Monthly Highlights September 2001	Hearsay
1/9/2002	ABB10569033		Calendar Entry Meeting ABT-773 Presentation	Hearsay
2/8/2002	ABB1247733 - ABBT247737		Interoffice Memorandum re: Monthly Highlights January 2002	Hearsay
4/9/2002	ABB1103547.ur - ABBT103551.ur		Interoffice Memorandum re: Monthly Highlights March 2002	Hearsay
1/18/2001	ABB10064814 - ABBT064817		Nisen Email re: Goodwin Philanthropy	Hearsay / Irrelevant
11/11/2000	ABB10107162		Silber Email re: Pharmacia meeting	Hearsay
1/9/2002	ABB10569033		Calendar entry - Meeting re: ABT-773 Presentation to Miles White	Hearsay
3/30/2004			Transcript of March 30, 2004 Hearing in Hancock I	Hearsay
6/15/2004	ABB10000077 - ABBT0000078		Desideri Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
2/11/2005	ABB10000182 - ABBT0000183		D'Amore Letter re: Research Funding Agreement Dated 03/14/01	Hearsay
2/11/2005	ABB10000038 - ABBT0000040		Davis Letter re: Research Funding Agreement Dated 03/13/01	Irrelevant
2/15/2005	ABB10000187 - ABBT0000188		D'Amore Letter re: Research Funding Agreement Dated 03/14/01	Hearsay
2/15/2005	ABB10000189 - ABBT0000190		Davis Letter re: Research Funding Agreement Dated 03/13/01	Hearsay
12/00/2001	ABB120514.ur - ABBT120558.ur		December 2001 PEC Presentation re ABT-773	Irrelevant
7/30/2002	JH001097 - JH001100		Notice of Termination of ABT-773 Hancock Notes	Authenticity / Irrelevant
1/9/2008			Poulos letter re: Research Funding Agreement Update Correction	Hearsay
8/22/2001	ABB1246353 - ABBT246368		Deemer Email re: outlicensing opportunities attaching introductory slides	Hearsay / Authenticity
9/28/2001	ABB1246248 - ABBT24652		Deemer Email re: Deemer Weekly Update	Hearsay

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
10/12/2001	ABB1246359		Deemer Email re: Licensing opportunities	Hearsay
10/26/2001	ABB10086829		Rosenthal Email re: ABT-518 and hematological cancer	Hearsay
10/24/2001	ABB1246338 - ABB124644		Deemer Email re: Update of ETAs Priority 1	Hearsay
1/25/2002	ABB10065300 - ABB10065335	Nisen Email re: Goodwin Slides	Hearsay / Irrelevant	
4/3/2002	ABB10170011 - ABB10170014	Hoff-Verk Email re: Salmedix ABT-518	Hearsay	
4/6/2002	ABB10141755 - ABB10141772	ABT-518 Selective Matrix Metalloproteinase MMP Inhibitor	Hearsay	
4/16/2002	ABB10089655	Hoff-Verk Email re: Salmedix Forwarding Jerry's Note	Hearsay	
5/3/2002	ABB10542887 - ABB10542892	Poulos Email re: April highlights	Hearsay	
8/2/2002	ABB10086988	Fitzgerald Email re: ABT-518 Outlicense Status	Hearsay	
8/13/2002	ABB10169420 - ABB10169421	Nabulsi Email re: John Hopkins Cancer Center and Abbott Oncology Collaboration Meeting	Hearsay	
8/14/2002	ABB10141711 - ABB10141728	Johns Hopkins 8-02.PPT; ABT-518 Selective Matrix Metalloproteinase MMP Inhibitor	Hearsay	
9/24/2003	ABB10091538 - ABB10091539	Hoff-Verk Email re: ABT-518 forwarding Prospective Licensee	Hearsay	
2/20/2004	ABB10167630 - ABB10167638	Asia Trip Report, Feb. 16-20, 2004, Perry Nisen	Hearsay	
5/25/2004	ABB10089550 - ABB10089551	Davidson Email re: ABT518 Negative Clinical Results with AG3340 and Marinastat	Hearsay	
5/31/2001	ABB10060145	Jansen Email re: M00235 Enrollment	Hearsay	
4/9/2001	ABB125535 - ABB125536	Kowalku Email re: Portfolio Probabilities	Hearsay	
1/25/2001	ABB1301935 - ABB1301941	Kowalku Email re: Summary of Success Probabilities	Hearsay (ABB1301935)	
9/19/2001	ABB10046892 - ABB10046902	Pain Table of Contents	Irrelevant	
00/00/2000	JHI021962 - JHI021979	Monte Carlo Analysis Work Paper	Hearsay / Irrelevant	
11/7/2002	ABB132502 - ABB132504	08/00/2005 Highlights	Hearsay	
00/00/0000	JH006641 - JH006643	John Hancock Development Portfolio Annual Progress Report	Hearsay / Authenticity / Incomplete / Irrelevant	
1/20/2003	ABB10578016 - ABB10578022	Pharmaceutical Products R&D Global Discovery Project Expense Report	Irrelevant	
12/00/2002	ABB10578023 - ABB10578025	Comprehensive Project Accounting System DiNGII Project Detail / 12/00/2002	Irrelevant	
6/7/2004	ABB10578026 - ABB10578031	Global Pharmaceutical Research and Development Global Development Project Expense Report Site	Irrelevant	
1/14/2005	ABB10578032 - ABB10578035	Global Pharmaceutical Research and Development Global Development Project Expense Report Site	Irrelevant	
12/00/2005	ABB10578036 - ABB10578038	Global Pharmaceutical Research and Development Global All	Irrelevant	

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
12/00/2001	ABBT0578039 - ABBT0578057		Compass Comprehensive Project Accounting System Dingh Project Detail	Hearsay / Authenticity / Irrelevant
05/00/2001	ABBT0556331 - ABBT0556331		Phase 2 Study of the Matrix Metalloprotease Inhibitor Pinomastat in Patients with Progressive Breast Cancer	Hearsay / Authenticity
5/14/2001	ABBT0556334 - ABBT0556349		Handwritten notes re: American Society of Clinical Oncology SF	Hearsay / Authenticity
00/00/2001	ABBT0556332 - ABBT0556333		Abstracts from Proceedings of ASCO Volume 20, 2001	Hearsay / Authenticity
10/19/2000	ABBT0061747 - ABBT0061748		Kysa Email re: MMPI press release	Incomplete / Hearsay
11/3/2000	ABBT0057776 - ABBT0057777;		Davidson Email re: JCO paper on Bayer compound	Multiple Documents / Hearsay
3/5/2001	ABBT0057787 - ABBT0057843		Drug document compound details for Marinastat!	Hearsay
8/3/2007	ABBT0026863 - ABBT0026866		Abbott's Amended Responses and Objections to Hancock's 2nd Set of Interrogatories	Hearsay
5/4/2000	JH001691 - JH001693	Klotz_0001	Klotz Letter re: General Biotechnology and Pharmaceutical Investments Consulting (Klotz 1)	No Objection
2/5/2001	ABBT328810 - ABBT328812	McCarthy_0038	McCarthy Email re: DSG with reply by Kowalek (McCarthy 38)	Hearsay
10/23/2001	ABBT246791 - ABBT246792	McCarthy_0061	McCarthy Email re: Non Confidential Briefing on ABT - 594 (McCarthy 61)	Hearsay
3/14/2003	JH002447 - JH002447	Mastromarino_0001	Welch Email re: Abbott Labs (Mastromarino 1)	No Objection
07/23/2001	ABBT103191.ur - ABBT103270.ur		ABT-773 Presentation	No Objection
2/8/2002	ABBT0027417 - ABBT0027432		Turner Email attaching year end reports	Hearsay
00/00/0000	ABBT0577855 - ABBT0577884		ABT-773 Out-licensing Documents	Multiple documents/Authenticity/Hearsay
3/5/2003	JH002419 - JH002420		Mangan Email re: February Early Warning Projection	No Objection
2/27/2006	JH1021946 - JH1021948		Hancock Loan Review Report	No Objection
00/00/0000			Moody Rating Symbols & Definitions	Authenticity/Irrelevant
11/25/2007			ALS Press Release identified as Exhibit 99.1 to Advanced Life Sciences Form 8-K for the period of November 15, 2007	No Objection
1/28/2008			Affidavit of Alan Friedman dated January 28, 2008	Hearsay
1/28/2008			Affidavit of Stephen Blewitt dated January 28, 2008	Hearsay
10/12/2007			Affidavit of Keith Hendricks dated October 12, 2007	Hearsay
10/23/2007			Supplemental Affidavit of Keith Hendricks dated October 23, 2007	Hearsay
10/17/2000	AL000481 - AL000521	Blewitt_0022	Draft Research Funding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Co Dated as of 10/00/2000 (Blewitt 22)	Irrelevant
03/00/2001	AL001323 - AL001377	Blewitt_0023	Research Funding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Co Dated as of 03/00/2001 (Blewitt 23)	Irrelevant
5/11/2000	JH000747 - JH000761	Blewitt_0036	Ketek Profile Report (Blewitt 36)	Hearsay / Irrelevant

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
12/20/2002	JH000807 - JH000817	Blewitt_0043	Letter re research Funding Agreement Dated as of 03/13/2001 (Blewitt 43)	Hearsay
8/10/2001	ABBT0049970 - ABBT0064233	Nisen_0031	Davidson Memo Results from the ABT-518 Clinical Trial (Nisen 31)	No Objection
4/10/2001	ABBT294218 - ABBT294247	Hopfield_0023	Redenbaugh - Mueller Email re: Fw Pharma Strategy Retreat Virus Checked (Hopfield 23)	Hearsay (ABBT294218-20)
10/29/1999	ABBT335520 - ABBT1335570	Collicott_0004	Abbott Laboratories ABT-594 Investigational New Drug IND Annual Report (Collicott 4)	No Objection
11/00/2000	ABBT144600.UR - ABBT144609.UR	Collicott_0018	ABT-594 Descriptive Memorandum November2000 (Collicott 18)	No Objection
01/18/2001	ABBT240417 - ABBT240417	Collicott_0030	Collicott Email re: ABT-594 Completion of Study for Neuropathic Pain (Collicott 30)	Hearsay
4/23/2001	ABBT001749 - ABBT001758	Collicott_0039	M99114 Study Review Presentation (Collicott 39)	No Objection
09/09/2001	ABBT003252 - ABBT003254		ABT-751 Project Information Report	No Objection
2/17/2008			Schedule 1A Illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Low Case	Hearsay/Untimely
2/17/2008			Schedule 1B Illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case	Hearsay/Untimely
2/17/2008			Schedule 2A Illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case	Hearsay/Untimely
2/17/2008			Schedule 2B Illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Low Case	Hearsay/Untimely
2/17/2008			Schedule 3A Illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Low Case	Hearsay/Untimely
2/17/2008			Schedule 3B Illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case	Hearsay/Untimely
2/17/2008			Schedule 4A Illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case	Hearsay/Untimely
2/17/2008			Schedule 4B Illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case	Hearsay/Untimely
2/17/2008			Schedule 5A and 5B Illustration of Change in Currently Expected Royalties - Low Case and Base Case	Hearsay/Untimely
2/17/2008			Schedule 6A Calculation of 1/3 of Unspent Aggregate Carryover Amount and Schedule 6B Abbott's Reported Program Spending by Compound	Hearsay/Untimely

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
2/17/2008			Schedule 7A Abbott Reported Spending in 2001, Schedule 7B 2002 Annual Research Plan, Schedule 7C Calculation of Expected/Nominal Ratio and Schedule 7D "Risk Adjusted" 2002 Preliminary Annual Research Plan	Hearsay/Untimely
3/23/2007	Davis_0001		Rule 30b6 Notice of Deposition of the Person or Persons Most Knowledgeable to Testify on Behalf of John Hancock Life Insurance Co, John Hancock Variable Life Insurance Co and Manulife Insurance Co fka Investors Partners Insurance Co in Re John Hancock Life Insurance Co et al vs Abbott Laboratories (Davis 1)	Irrelevant
3/23/2007		Davis_0002	John Hancock's Objections and Responses to Abbott Laboratories First Set of Interrogatories in Re John Hancock Life Insurance Co et al vs Abbott Laboratories (Davis 2)	No Objection
9/21/2000	JH005573 - JH005573	Davis_0003	Bond Investment Committee Meeting Minutes (Davis 3)	No Objection
9/21/2000	JH001203 - JH001220	Davis-0004	Purchase Recommendation For Abbott Laboratories (Davis 4)	No Objection
6/28/2001	JH1021462 - JH1021462	Davis_0005; Daeser 0001	GBSA Spreads to On the Run Treasuries (Davis 5)	No Objection
5/8/2000	JH002423 - JH002429	Davis_0006	Blewitt Memo re: Proposed John Hancock Abbott Laboratories Transaction (Davis 6)	No Objection
9/21/2000	JH002414 - JH002414	Davis_0007	Hartz Email re: Abbott (Davis 7)	Hearsay
10/10/2000	JH005551 - JH005553	Davis_0008	Committee of Finance Records (Davis 8)	No Objection
3/13/2001	JH008076 - JH001105	Davis_0009	Research Funding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Co et al.	Multiple Documents
00/00/0000	JH001103 - JH001104	Davis_0010	Memo re: Commitment to Fund Research and Development Expenses for Abbott Laboratories	No Objection
6/16/2004	ABBT0000077 - ABBT0000078	Martinez_0001	Desideri Letter re: Research Funding Agreement (Martinez_0001)	Hearsay
4/12/2004	JH1011883 - JH1011886	Martinez_0002	Blewitt Letter re: Research Funding Agreement (Martinez 2)	No Objection
7/19/2004	ABBT0000265 - ABBT0000266	Martinez_0003	Campbell Email re: Hancock Audit (Martinez 3)	No Objection

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
8/31/2004	ABBT0000257 - ABBT0000260	Martinez_0005	Campbell Email re: John Hancock Audit (Martinez 5)	No Objection
10/26/2004	ABBT0000250 - ABBT0000253	Martinez_0006	Campbell Email re: Status on Documents Available for Review (Martinez 6)	No Objection
3/15/2005	ABBT0000280 - ABBT0000284	Martinez_0009	Campbell Email re: JH Abbott Audit Documentation (Martinez 9)	No Objection
3/17/2005	JHII021526 - JHII021594	Martinez_0010	John Hancock Document Index Report (Martinez 10)	No Objection
3/11/2005	JHII021637 - JHII021643	Martinez_0019	Summary of Available Monthly Project Status Reports as of 03/11/2005 (Martinez 19)	No Objection
3/13/2001	JHII021607 - JHII021611	Martinez_0020	Compound Summary Matrix Metalloproteinase Inhibitor MMPI Program ABT-518 Overview Research Funding Agreement Highlights (Martinez 20)	No Objection
3/13/2001	JHII021612 - JHII021619	Martinez_0021	Compound Summary Cholinergic Channel Modulator ABT-594 Overview Research Funding Agreement Highlights (Martinez 21)	No Objection
00/00/2000	JHII021620 - JHII021626	Martinez_0022	Compound Summary Cholinergic Channel Modulator ABT-594 Report (Martinez 22)	No Objection
00/00/2003	JHII021627 - JHII021635	Martinez_0023	Compound Summary Dopamine Receptor Agonist Program ABT-724 Report (Martinez 23)	No Objection
3/25/2005	ABBT0000270 - ABBT0000271	Hair_0003	Campbell Email re: John Hancock Audit (Hair 3)	No Objection
3/22/2005	ABBT0000273 - ABBT0000276	Hair_0004	Hair Email re: JH Abbott Audit Documentation (Hair 4)	No Objection

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
4/5/2005	ABBT0000215 - ABBT0000220	Hair_0002	Davis Email re John Hancock/Abbott audit issues (Hair 2)	No Objection
3/18/2005	ABBT0000277 - ABBT0000279	Hair_0005	Hair Email re: JH Abbott Audit Documentation (Hair 5)	No Objection
12/31/2001	JHII021496 - JHII021498	Daesen_0004	Schedule BA Project Equity Drug Investments YTD Report (Daesen 4)	No Objection
3/26/2002	JH002659 - JH002659	Daesen_0006	Mangan Email re: Abbott Labs (Daesen 6)	No Objection
6/27/2000	AL000115 - AL000119	Lee_0002	Proposed Summary of Terms Agreement (Lee 1)	No Objection
8/17/2000	AL000138 - AL000175	Lee_0003	Deemer Email re: Draft Agreement (Lee 3)	No Objection
10/4/2000	JH003270 - JH003341	Lee_0006	Email re: Abbott John Hancock Research Funding Agreement (Lee 6)	Irrelevant
	JH008378 - JH008384	Lee_0017	Lee Facsimile re: Draft Research Funding Agreement	Irrelevant/Hearsay
6/8/2000	JHII012376 - JHII012388	Hartz_0002	Report re: Purchase Recommendation	No Objection
9/19/2000	JH003551 - JH003555	Hartz_0003	Email report re: Abbott	No Objection
4/19/2000	JH003561 - JH003561	Hartz_0011	Email re: More Model	No Objection

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
5/8/2000	JH002423 - JH002429	Hartz_0014	Memo re: Proposed John Hancock Abbott Laboratories Transaction	No Objection
9/21/2000	JH005573 - JH005573	Hartz_0019	Meeting Minutes re: Bond Investment Committee 09/21/2000	No Objection
3/13/2001	JH001103 - JH001104	Hartz_0025	Memo re: Abbott Laboratories Non Recourse	No Objection
3/26/2002	JH002659 - JH002659	Hartz_0026	Email re: Abbott Labs	No Objection
9/30/2002	JH003142 - JH003158	Hartz_0027	Email re: Abbott Labs	No Objection
3/27/2003	JH002407 - JH002409	Hartz_0032	Email memo re: Abbott Laboratories Research and Funding Agreement	No Objection
6/11/2003	JH003113 - JH003115	Hartz_0037	Email re: Abbott Research and Development Agreement	No Objection
6/17/2003	JH003107 - JH003112	Hartz_0038	Email and Report re: Abbott Valuation	No Objection
12/19/2003	JH004479 - JH004480	Hartz_0039	Email re: John Hancock vs. Abbott Laboratories	no Objection
2/24/2005	JH1011221 - JH1011221	Hartz_0045	Email re: Abbott	No Objection
12/21/1999	ABBT0051889 - ABBT0051889	Thomas_0001	114 Sample Size	No Objection

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
3/7/2001	MCK00377 - MCK00386	Hopfield_0004	Presentation re: Building A World of Opportunities Together Development Portfolio Review Kick Off 03/07/2001	No Objection
			Expert Report of Avram Tucker Report Support Binders Volume I-3	Untimely
			Expert Report of Avram Tucker Exhibit Support Binders	Untimely
3/13/2001	MCK00423 - MCK00430	Hopfield_0005	Please Print and Put in Mail Folder	No Objection
07/00/0000	MCK00431 - MCK00437	Hopfield_0006	Initial Portfolio Prioritization	No Objection
3/19/2001	MCK00348 - MCK00376	Hopfield_0007	R&D Integration Update Discussion Document 03/19/2001	No Objection
04/00/2001	MCK00276 - MCK00347	Hopfield_0008	Overview of Abbott R&D Fact Pack April 2001	No Objection
4/10/2001	ABBT32300 - ABBT323305	Hopfield_0009	Pharma Strategy Retreat on May 24, 2000	No Objection
5/5/2001	MCK00204 - MCK00275	Hopfield_0010	Resource Allocation Across GPRD Discussion Document 05/05/2001	No Objection
5/6/2001	MCK00408 - MCK00422	Hopfield_0011	Hopfield Email re: R& D Strategy Retreat Input	No Objection
06/00/2000	ABBT0570747 - ABBT0570770	Meyer_0003	ABT773 Ketolide Antibiotic 2000 Strategic Marketing Plan 06/00/2000	No Objection
9/13/2000	ABBT0557552 - ABBT0557557	Meyer_0004	ABT-773 Dev Plan	No Objection

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
11/28/2000	ABBT0558150 - ABBT0558150	Meyer_0005	Executive Summary of ABT-773 End of Phase 2 Mig with FDA	No Objection
11/29/2000	ABBT0556816 - ABBT0556822	Meyer_0006	Slides for 12/05/2000 Meeting	No Objection
12/5/2000	ABBT0577000 - ABBT0577168	Meyer_0007	ABT-773 Portfolio Review 12/05/2000	No Objection
02/01/2001	ABBT0000387 - ABBT0000399	Meyer_0008	February 2001 ABT-773 Tab Ketolide Antibiotic Tablet	No Objection
2/12/2001	ABBT205042 - ABBT205046	Meyer_0009	ABT-773 Update 02/12/2001	No Objection
2/22/2001	ABBT204955 - ABBT205041	Meyer_0011	773 Material	No Objection
2/14/2001	ABBT0568172 - ABBT0568172	Meyer_0012	Re: Studies to Meet Pediatric Rule Requirements	No Objection
02/00/2001	JH008153 - JH008158	Meyer_0015	ABT-773 Descriptive Memorandum February 2001	No Objection
3/9/2000	ABBT0141929 - ABBT0141983	Nabulsi_0001	Presentation re: Matrix Metalloproteinase Inhibitors Project Discovery Development Candidate Meeting 03/09/2000 A291518 for Treatment of Cancer	No Objection
08/00/2000	ABBT0052083 - ABBT0092094	Nabulsi_0003	Report re: ABT-518 Transition Strategy MMPI	No Objection
02/00/2001	ABBT0000343 - ABBT0000348	Nabulsi_0006	Project Status Report re: February 2001 ABT-518 Matrix Metalloproteinase Inhibitor	No Objection
3/9/2001	ABBT0013224 - ABBT0013232	Nabulsi_0009	Presentation re: Abbott Portfolio review March 7-9, 2001	No Objection
3/8/2001	ABBT0045253 - ABBT0045253	Nabulsi_0010	Meeting Documents re: MMPI Monthly Meeting Agenda 03/08/2001	No Objection
3/8/2001	ABBT300143 - ABBT300144	Nabulsi_0011	Meeting Documents MMPI Working Group Meeting Minutes 03/08/2001	No Objection
		ABBT0507866 - ABBT0507866	Memo re: Project review	No Objection
12/11/2001	ABBT0518377 - ABBT0518378	Nabulsi_00013	Report re: Timeline of Events Occurring with Study M00235 in the Netherlands	No Objection
3/12/2001	ABBT0060788 - ABBT0060788	Nabulsi_00014	Email re: M00235 Update	No Objection

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
5/25/2001	ABBT0051200 - ABBT0061200	Nabulsi_00017	Email re: ABT-518	No Objection
4/12/2001	ABBT0045243 - ABBT0045245	Nabulsi_00021	Meeting Documents re: MMPI Monthly Meeting Agenda 04/12/2001	No Objection
05/09/2001	ABBT143915.UR - ABBT143920.UR	Nabulsi_00024	Project Status report: May 2001 ABT-518 Matrix Metalloproteinase Inhibitor	No Objection
00/00/2001	ABBT0059550 - ABBT0059556	Nabulsi_00026	Presentation re: ASCO 2001 MMPI Update	No Objection
1/15/1999	ABBT005027 - ABBT005030	Meyer_00001	01/15/1999 Meeting Minutes Analgesia Venture Portfolio Review	No Objection
04/00/1999	ABBT0020594 - ABBT0020611	Meyer_00003	ABT-259 Transition Strategy	No Objection
2/2/2001	ABBT314925 - ABBT314926	Meyer_00012	DSG	Hearsay
2/19/2001	ABBT0115991 - ABBT0115993	Meyer_00013	Scientific Strategy for ABT-594 NNR Tolerability	No Objection
03/00/2001	ABBT0024132 - ABBT0024153	Meyer_00016	Global Pharmaceutical Discovery Internal Review 03/00/2001 Book Number 27	No Objection
3/8/2001	ABBT298379 - ABBT298379	Meyer_00018	ABT-594 Pain Strategy DSG 03/05/00 Meeting Minutes	No Objection
3/12/2001	ABBT0022006 - ABBT0022008	Meyer_00019	Calendar Entry	No Objection

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
4/23/2001	ABBT0001749 - ABBT0001758	Meyer_00020	M99114 Study Review	No Objection
6/7/2002	ABBT0108742 - ABBT0108779	Meyer_00026	DDC Slides	No Objection
6/13/2002	ABBT0023982 - ABBT0024053	Meyer_00027	DDC A429202 Nicotinic Receptor NN Agonist	No Objection
		Meyer_00029	Neuroscience and Pain	No Objection
9/13/2000	ABBT0557552 - ABBT0557557	Fox_00002	Email re: ABT-773 Dev Plan	No Objection
11/20/2000	ABBT0558681 - ABBT0558683	Fox_00003	Email report re: FDA Telephone Contract report ABT-773	No Objection
2/12/2001	ABBT205042 - ABBT205046	Fox_00008	report re: ABT-773 Update 02/12/2001	No Objection
2/14/2001	ABBT0568172 - ABBT0568172	Fox_00010	Email re: Studies to Meet Pediatric Rule requirements	No Objection
3/13/2001	JH008076 - JH008211	Leiden_0001	Letter Agreement re: Research Funding Agreement Dated as of 03/13/2001	No Objection
3/9/2001	ABBT0092919 - ABBT0092921	Leiden_0005	Meeting Documents re: Portfolio Review Meeting 03/07/2001 to 03/09/2001 the Hyatt Deerfield	No Objection
07/00/0000	ABBT0155602 - ABBT0155608	Leiden_0007	Report re: Initial Portfolio Prioritization	No Objection

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
09/00/2000	ABBT0155493 - ABBT0155512	Leiden_0010	Presentation re: Pharmaceuticals Strategy Update 09/00/2000	No Objection
09/00/2000	ABBT0577835 - ABBT0577854	Leiden_0011	Presentation re Pharmaceuticals Strategy Update 09/00/2000	No Objection
10/12/2000	ABBT0118072 - ABBT0118072	Leiden_0014	Email re: NNR Documents	No Objection
12/00/2000	ABBT0004460 - ABBT0004464	Leiden_0020	Project Status Report re: 12/00/2000 ABT-594 Project Status Report	No Objection
3/2/2001	ABBT0037509 - ABBT0037608	Leiden_0022	Memo Report re 00/00/2001 Plan Final Reference Package	No Objection
12/11/2001	ABBT0518377 - ABBT0518378	Leiden_0030	Report re: Timeline of Events Occurring with Study M00235 in the Netherlands	No Objection
10/9/2001	ABBT0148334 - ABBT0148334	Leiden_0033	Email re: ABT-594 Not Funded	No Objection
1/18/2005	ABBT0000235 - ABBT000023	Martinez_0008	Martinez Email re: Audit Thursday (Martinez 8)	No Objection
5/8/2004	JHI021505 - JHI021525	Martinez_0016	Davis Invoice No. 1017 for the amount of \$7975.30 (Martinez 16)	No Objection
9/30/2005	JHI021501 - JHI021504	Martinez_0017	John Hancock Abbott Choate Hall and Stewart Stone Turn Time Sheet Report (Martinez 17)	No Objection
5/20/2001	ABBT0064234 - ABBT0064234	Nabulsi_0025	Nisen Email re: MMPI Summary of ASCO Studies (Nabulsi 25)	No Objection
00/00/0000	ABBT0556321 - ABBT0556349	Nabulsi_0027	Summary of Healthy Volunteer Data for BMS275291 Presentation (Nabulsi 27)	No Objection
6/21/2001	ABBT0507879 - ABBT0507879	Nabulsi_0029	Nabulsi Letter re: Study of ABT518 in Men and Women (Nabulsi 29)	No Objection

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
8/10/2001	ABBT0049970 - ABBT0049977	Nabulsi_0034	Davidson Report re: ABT518 (Nabulsi 34)	No Objection
1/8/2001	ABB T240624 - ABB T240624	Collicott_0028	Collicott Email re: M9914 Crf Tracking (Collicott 28)	Hearsay
3/17/2005	JHI021526 - JHI021594	Hair_0011	Report of John Hancock Document Index (Hair 11)	No Objection
3/28/2005	JHI021598 - JHI021598	Hair_0013	Report of Documents that were Received by Stone Turn but not Identifiable or Previously Included in the Document Index (Hair 13)	No Objection
3/9/2005	JHI021636 - JHI021636	Hair_0015	Report of John Hancock Abbott Research Funding Agreement Audit MH Notes (Hair 15)	No Objection
3/11/2005	JHI021637 - JHI021637	Hair_0016	Report of John Hancock Abbott Summary of Available Monthly Project Status Reports (Hair 16)	No Objection
06/00/2003	JHI021645 - JHI021646	Hair_0018	Report of Reviewers Compound Report (Hair 18)	No Objection
3/18/2005	JHI021638 - JHI021643	Hair_0019	Report of John Hancock Abbott Summary of Available Monthly Highlights (Hair 19)	No Objection
3/16/2005	JHI021644 - JHI021644	Hair_0020	Report of John Hancock Abbott Summary of Available Monthly Project Status Reports (Hair 20)	No Objection
3/13/2001	JHI021607 - JHI021611	Hair_0021	Report of John Hancock Abbott Compound Summary Matrix Metalloproteinase Inhibitor MMPI Program ABT-518 (Hair 21)	No Objection
3/13/2001	JHI021612 - JHI021619	Hair_0022	Report of John Hancock Abbott Compound Summary Cholinergic Channel Modulator ABT-594 (Hair 22)	No Objection
9/6/2005	JHI012056 - JHI012061	Blewitt_0030	Blewitt Memorandum attaching Draft Request Number 85 Followup Valuation of Sch BA Part 1 Assets Abbott Laboratories (Blewitt 30)	Hearsay
6/5/2000	ABBT246466 - ABBT246471	Blewitt_0032	ABT-773 Descriptive Memorandum May 2000 (Blewitt 32)	No Objection
5/11/2000	JH000747 - JH000761	Blewitt_0036	Ketek Profile Report (Blewitt 36)	Hearsay/Irrelevant
9/19/2000	JH003551 - JH003555	Blewitt_0014	Hartz Email re: Abbott Modeling the Expect Returns and Expected Loss Report (Blewitt 14)	No Objection
03/00/2001	JH006002 - JH006009	Blewitt_0024	Research Funding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Co. et al. dated as of 03/00/2001 9 (Blewitt 24)	Hearsay/Irrelevant
4/1/2005	JHI011911 - JHI011915	Blewitt_0028	Faxed letter re: Research Funding Agreement dated as of 03/13/2001 (Blewitt 28)	No Objection
1/11/2001	ABBT0045264 - ABBT0045269	Loberg_0003	MMPI Working Group Meeting Minutes dated 01/11/2001 (Loberg 3)	No Objection
5/11/2001	ABBT0045302 - ABBT0045304	Loberg_0010	Oncology Status Report as of 05/11/2001 (Loberg 10)	No Objection
02/00/2001	ABBT000343 - ABBT000348	Hair_0017	Project Status Report for ABT-518 Matrix Metalloproteinase Inhibitor May 2001 (Hair 17)	No Objection
6/3/2004	ABBT0126520 - ABBT0126520	Campbell_0010	Campbell Email re: Hancock Audit (Campbell 10)	Hearsay
6/4/2004	ABBT012650 - ABBT0126592	Campbell_0011	Wendrick Email re: Hancock Audit (Campbell 11)	Hearsay
6/10/2004	ABBT019051 - ABBT0190552	Campbell_0012	Pavelski Email re Hancock Audit (Campbell 12)	Hearsay

Abbott Laboratories' List of Objected To Trial Exhibits

Date	Production Range	Deposition Exhibit No.	Description	Hancock Objections
6/10/2004	ABBT0190544 - ABBT0190549	Campbell_0014	Wendrick Email re: Hancock Audit Monday (Campbell 14)	Hearsay
8/5/2004	ABBT0000125 - ABBT0000127	Campbell_0021	Letter re: Research Funding Agreement Between Abbott Laboratories Abbott and John Hancock Life Insurance Co. et al. dated 03/13/2001 (Campbell 21)	Hearsay